Background: The aim of the rapid introduction of vaccines during the COVID-19 pandemic was a reduction in SARS-CoV-2 transmission and a less frequent occurrence of severe COVID-19 courses.Thus, we evaluated COVID-19 severity in vaccinated individuals to examine variant-specific symptom characteristics and their clinical impact on the serological immune response.Methods: A total of 185 individuals previously vaccinated against and infected with the SARS-CoV-2 Delta (B.1.617.
2) or Omicron (BA.4 and BA.5) variant, were enrolled MENO SENSE for anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig level detection.A structured survey regarding medical history was conducted.Results: In 99.
5 percent of cases, outpatient treatment was satisfactory.Specific symptoms associated with variants included ageusia and anosmia in patients with Delta infections and throat pain in Omicron infections.Among Delta-infected individuals with specific symptoms, significantly higher levels of anti-N antibodies were observed.Conclusion: Our study identified variant-specific differences in the amount of SARS-CoV-2 antibody production and COVID-19 symptoms.Despite this, vaccinated individuals with Omicron or Delta infections generally experienced mild disease courses.
Additionally, asymptomatic individuals exhibit lower anti-SARS-CoV-2 antibody levels, indicating a clinical correlation between disease-specific antibodies and distinct symptoms, EGCG particularly in the case of the Delta variant.In follow-up studies, exploring post-COVID syndrome and focusing on cognitive symptoms in the acute phase of Omicron infections is crucial as it has the potential to longitudinally impact the lives of those affected.